APLS logo

Apellis Pharmaceuticals, Inc. Common Stock

APLS

APLS: Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

more

Show APLS Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of APLS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by APLS's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods of treating chronic disorders with complement inhibitors Aug. 01, 2023
  • Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof May. 30, 2023
  • Patent Title: Rnas for complement inhibition Nov. 29, 2022
  • Patent Title: Cell-penetrating compstatin analogs and uses thereof Aug. 09, 2022
  • Patent Title: Combination therapy for c3 inhibition May. 24, 2022
  • Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods Apr. 05, 2022
  • Patent Title: Detection of high risk drusen Apr. 05, 2022
  • Patent Title: Dosing regimens and related compositions and methods Jun. 22, 2021
  • Patent Title: Methods of treating chronic disorders with complement inhibitors May. 25, 2021
  • Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof May. 11, 2021
  • Patent Title: Cell-penetrating compstatin analogs and uses thereof Mar. 09, 2021
  • Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods Dec. 29, 2020
  • Patent Title: Compstatin analogs for treatment of neuropathic pain Jun. 30, 2020
  • Patent Title: Methods of selecting compstatin mimetics Sep. 10, 2019
  • Patent Title: Cell-penetrating compstatin analogs and uses thereof Jun. 04, 2019
  • Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof Nov. 13, 2018
  • Patent Title: Methods of treating chronic disorders with complement inhibitors Aug. 07, 2018
  • Patent Title: Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods Jul. 31, 2018
  • Patent Title: Compstatin analogs for treatment of neuropathic pain Aug. 23, 2016
  • Patent Title: Complement assays and uses thereof Mar. 22, 2016
  • Patent Title: Local complement inhibition for treatment of complement-mediated disorders Nov. 12, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of APLS in WallStreetBets Daily Discussion

APLS News

Recent insights relating to APLS

CNBC Recommendations

Recent picks made for APLS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in APLS

Corporate Flights

Flights by private jets registered to APLS